Abstract: The present invention relates to host cells expressing monomeric streptavidin. The host cells according to the present invention may express streptavidin in vivo, making it possible to visualize and monitor in real time the biodistribution of cancer tissue, pre-targeted by the host cell, with a biotinylated diagnostic agent, as well as to increase the cancer-targeting efficiency of biotinylated anticancer drugs.

Abstract: The present invention relates to a monomeric streptavidin-expressing gene construct and a host cell into which a recombinant vector comprising the gene construct has been introduced. The gene construct according to the present invention, after injected in vivo through a strain, may express streptavidin, thereby making it possible not only to monitor in real time the location of the strain or a cancer tissue pre-targeted by the strain by using a biotinylated diagnostic agent, but also to increase the cancer targeting efficiency of a biotinylated anticancer agent.

Abstract: The present invention relates to a Salmonella strain that selectively acts on cancer for the treatment of cancer, and a composition for preventing or treating cancer containing the same. In particular, the Salmonella strain according to the present invention has a tumor-suppressing effect, but has a significantly low viability in normal organs, and thus may have a significant anticancer effect compared to conventional inventions.

Abstract: The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging.

Abstract: The present disclosure relates to a DNA construct, and a strain into which a recombinant vector comprising the DNA construct has been introduced. The DNA construct according to the present disclosure allows the expression levels of genes, operably linked downstream of first and second promoters, in a host strain or cell, to be balanced, so that cancer diagnosis and treatment may be performed simultaneously. In addition, the DNA construct of the present disclosure completely does not allow the anticancer protein and the reporter protein to be expressed at all in the absence of doxycycline, and thus it allows the anticancer protein to be expressed at an appropriate dose for cancer treatment by controlling whether or not treatment with doxycycline is performed, and at the same time, enables the size of the cancer to be monitored in real time depending on the expression level of the reporter protein.

Abstract: The present invention provides a composition for diagnosing fungal infection comprising 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS) as an effective ingredient.

Abstract: The present invention relates to a radioactive compound with improved targeting ability for melanoma and a pharmaceutical composition for the treating melanoma comprising the same, and the targeting ability for melanoma is improved as compared to the conventional contrast agent for melanoma. The radioactive compound according to an embodiment of the present invention shows a very excellent therapeutic effect on melanoma.

Abstract: The present invention relates to a curcumin derivative, a method for producing same, and a photo-acoustic imaging agent comprising the curcumin derivative for detecting beta-amyloid plaque. The curcumin derivative, expressed by chemical formula 1, according to the present invention exhibits superb selective bonding with beta-amyloid, thereby allowing beta-amyloid to be detected by means of an optical or photo-acoustic imaging methods, and, particularly, the curcumin derivative can highly effectively detect photo-acoustic signals with almost no noise by reacting to irradiation of light having a particular wavelength range, and thus can be useful as a composition for detecting beta-amyloid and for diagnosing diseases caused by excessive production of beta-amyloid.

Abstract: The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging.

Abstract: The present invention relates to a curcumin derivative, a method for producing same, and a photo-acoustic imaging agent comprising the curcumin derivative for detecting beta-amyloid plaque. The curcumin derivative, expressed by chemical formula 1, according to the present invention exhibits superb selective bonding with beta-amyloid, thereby allowing beta-amyloid to be detected by means of an optical or photo-acoustic imaging methods, and, particularly, the curcumin derivative can highly effectively detect photo-acoustic signals with almost no noise by reacting to irradiation of light having a particular wavelength range, and thus can be useful as a composition for detecting beta-amyloid and for diagnosing diseases caused by excessive production of beta-amyloid.

Abstract: A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli (E. coli), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.

Abstract: To provide a bacterium-based microrobot which can be specifically targeted to cancer in vivo, the present invention provides a drug delivery system for cancer tissue, comprising a bacterium, and a microbead encapsulated with at least one drug, wherein biotin is bound to a surface of the bacterium and a surface of the microbead is coated with streptavidin.

Abstract: A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli (E. coli), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.

Abstract: The present invention relates to bacteria which specifically target infarcted tissue and use thereof. The present invention provides a selective infarcted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infarcted tissue or in selectively imaging the infarcted tissue. The infarcted tissue-targeting bacterium of the present invention can finish treatments by using antibiotics, and therefore, have remarkable advantages as compared to gene therapy using recombinant viruses. The infarcted tissue-targeting bacterium of the present invention have a significantly high affinity and specificity to infarcted myocardium or infarcted brain, thereby significantly reducing undesired transfections in the organs or tissues other than the heart. The gene expression by the infarcted tissue-targeting bacterium of the present invention in infarcted myocardium or infarcted brain is remotely controllable.

Abstract: To provide a bacterium-based microrobot which can be specifically targeted to cancer in vivo, the present invention provides a drug delivery system for cancer tissue, comprising a bacterium, and a microbead encapsulated with at least one drug, wherein biotin is bound to a surface of the bacterium and a surface of the microbead is coated with streptavidin.

Abstract: The present invention relates to bacteria which specifically target infracted tissue and use thereof. The present invention provides a selective infracted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infracted tissue or in selectively imaging the infracted tissue. The infracted tissue-targeting bacterium of the present invention can finish treatments by using antibiotics, and therefore, have remarkable advantages as compared to gene therapy using recombinant viruses. The infracted tissue-targeting bacterium of the present invention have a significantly high affinity and specificity to infracted myocardium or infracted brain, thereby significantly reducing undesired transfections in the organs or tissues other than the heart. The gene expression by the infracted tissue-targeting bacterium of the present invention in infracted myocardium or infracted brain is remotely controllable.

Abstract: Provided are a bacterium-based microrobot for medical treatment, an operation method thereof, and a treatment method using the same. The bacterium-based microrobot can be propelled by the flagellum movement of bacteria, can be directed toward a target lesion by the ability of bacteria to recognize the lesion, can be monitored for how many the microrobot targets the lesion, and can directly or indirectly treat the lesion by the proliferation of bacteria through self-division in the lesion. The bacteria may be genetically manipulated to be resistant to immune responses and produce a material inhibitory of the growth of affected cells.